102 related articles for article (PubMed ID: 18347556)
21. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy.
Paik S
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1019s-1023s. PubMed ID: 16467119
[TBL] [Abstract][Full Text] [Related]
22. Development of the 21-gene assay and its application in clinical practice and clinical trials.
Sparano JA; Paik S
J Clin Oncol; 2008 Feb; 26(5):721-8. PubMed ID: 18258979
[TBL] [Abstract][Full Text] [Related]
23. A new look at node-negative breast cancer.
Harbeck N; Thomssen C
Oncologist; 2010; 15 Suppl 5():29-38. PubMed ID: 21138953
[TBL] [Abstract][Full Text] [Related]
24. Advances in diagnosis and therapies for breast cancer.
Giguere JK
J S C Med Assoc; 1998 Jun; 94(6):254-6. PubMed ID: 9648406
[TBL] [Abstract][Full Text] [Related]
25. Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score.
Gwin K; Pinto M; Tavassoli FA
Int J Surg Pathol; 2009 Aug; 17(4):303-10. PubMed ID: 19578051
[TBL] [Abstract][Full Text] [Related]
26. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Ademuyiwa FO; Miller A; O'Connor T; Edge SB; Thorat MA; Sledge GW; Levine E; Badve S
Breast Cancer Res Treat; 2011 Apr; 126(3):797-802. PubMed ID: 21197567
[TBL] [Abstract][Full Text] [Related]
27. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
Kelly CM; Krishnamurthy S; Bianchini G; Litton JK; Gonzalez-Angulo AM; Hortobagyi GN; Pusztai L
Cancer; 2010 Nov; 116(22):5161-7. PubMed ID: 20665886
[TBL] [Abstract][Full Text] [Related]
28. A new look at node-negative breast cancer.
Harbeck N; Thomssen C
Oncologist; 2011; 16 Suppl 1():51-60. PubMed ID: 21278441
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
30. The influence of a gene expression profile on breast cancer decisions.
Henry LR; Stojadinovic A; Swain SM; Prindiville S; Cordes R; Soballe PW
J Surg Oncol; 2009 May; 99(6):319-23. PubMed ID: 19204954
[TBL] [Abstract][Full Text] [Related]
31. [Adjuvant chemotherapy in primary carcinoma of the breast].
Harbeck N
Zentralbl Gynakol; 2003 Sep; 125(9):322-6. PubMed ID: 14569511
[TBL] [Abstract][Full Text] [Related]
32. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
33. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
[TBL] [Abstract][Full Text] [Related]
34. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
35. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
[TBL] [Abstract][Full Text] [Related]
36. Women's experiences with genomic testing for breast cancer recurrence risk.
Tzeng JP; Mayer D; Richman AR; Lipkus I; Han PK; Valle CG; Carey LA; Brewer NT
Cancer; 2010 Apr; 116(8):1992-2000. PubMed ID: 20213682
[TBL] [Abstract][Full Text] [Related]
37. Algorithm for in vitro diagnostic multivariate index assay.
Kato K
Breast Cancer; 2009; 16(4):248-51. PubMed ID: 19585214
[TBL] [Abstract][Full Text] [Related]
38. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update).
Levine M;
CMAJ; 2001 Jan; 164(2):213. PubMed ID: 11332317
[No Abstract] [Full Text] [Related]
39. Treatment options for early breast cancer in elderly women.
Basso U; Brunello A; Pogliani C; Monfardini S
Expert Rev Anticancer Ther; 2004 Apr; 4(2):197-211. PubMed ID: 15056050
[TBL] [Abstract][Full Text] [Related]
40. Factors affecting the adoption and use of gene expression profiling by oncologists in clinical practice.
Patil D; Issa AM
Per Med; 2015 Jan; 12(1):33-42. PubMed ID: 29767541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
